VEGFA and endophthalmitis: Conversely, studies report that the incidence of endophthalmitis was similar after the administration of three different anti-VEGF agents: bevacizumab, 0.013%; ranibizumab, 0.016%; and aflibercept, 0.016%.1 The reason for this discrepancy might be that, currently, ranibizumab is used with prefilled syringes, whereas aflibercept has a conventional preparation.